Predictors associated with treatment initiation and switch in a real-world chronic hepatitis B population from five European countries
| Autor: | H, Leblebicioglu, V, Arama, X, Causse, P, Marcellin, R, Ozaras, B, Postawa-Klozinska, K, Simon, A I, Suceveanu, M, Wiese, S, Zeuzem, I, Klauck, E, Morais, S, Bjork, B, Lescrauwaet, D, Kamar, J P, Zarski, Tansu, Yamazhan |
|---|---|
| Přispěvatelé: | Ondokuz Mayıs Üniversitesi, Service d'hépatologie, Hôpital Beaujon-Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), The AI463‐121 European Longitudinal Chronic Hepatitis B Study Group, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP) |
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male adefovir medicine.medical_specialty Adolescent [SDV]Life Sciences [q-bio] Population antiviral treatment Antiviral Agents Young Adult Hepatitis B Chronic Chronic hepatitis Virology Cox proportional hazards regression medicine Adefovir Humans In patient chronic hepatitis B Longitudinal Studies Prospective Studies education ComputingMilieux_MISCELLANEOUS Aged Aged 80 and over education.field_of_study Geography Hepatology Adult patients business.industry Lamivudine Alanine Transaminase Entecavir Middle Aged Viral Load tenofovir 3. Good health Surgery Europe Infectious Diseases Female lamivudine business [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology Demography medicine.drug entecavir |
| Zdroj: | Journal of Viral Hepatitis Journal of Viral Hepatitis, Wiley-Blackwell, 2014, 21 (9), pp.662-670. ⟨10.1111/jvh.12202⟩ |
| ISSN: | 1352-0504 1365-2893 |
| DOI: | 10.1111/jvh.12202⟩ |
| Popis: | Leblebicioglu, Hakan/0000-0002-6033-8543; Suceveanu, Andra Iulia/0000-0001-8669-4952; Simon, Krzysztof/0000-0002-8040-0412 WOS: 000340391600010 PubMed: 24329883 In Europe, healthcare systems differ between countries and different factors may influence Chronic hepatitis B (CHB) treatment choices in different counties. This analysis from a prospective, longitudinal, non-interventional study in five EU countries aimed to explore determinants associated with treatment initiation or switch in patients with CHB. A total of 1267 adult patients with compensated CHB in Germany, France, Poland, Romania and Turkey were prospectively followed for up to 2years (March 2008-December 2010). Determinants of treatment initiation or switch were analysed using multivariate Cox proportional hazards regression. Median time since CHB diagnosis was 2.6 (0-37.7)years. Among 646 treatment-naive patients, the probability of treatment initiation during follow-up was higher: in Germany (P=0.0006), Poland (P2xULN (P=0.0523) compared with ALT 1xULN; and in patients with hepatitis B virus (HBV) DNA 2000IU/mL (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text